on SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Reports Robust Growth in Q2 of Fiscal Year 2024
SCHOTT Pharma AG & Co. KGaA has announced an 11% year-on-year increase in Q2 2024 revenues to EUR 247 million at constant currencies. The EBITDA margin stood at 27.0%, reflecting strategic ramp-up costs. High-value solutions (HVS) accounted for 53% of total revenues, demonstrating strong demand and driving overall growth.
CEO Andreas Reisse emphasized the company’s strong market position, supported by enduring partnerships and an expansive portfolio. SCHOTT Pharma advances in the large volume drug administration sector, collaborating with KORU Medical Systems for subcutaneous infusion therapies.
CFO Dr. Almuth Steinkühler highlighted satisfaction with revenue momentum and reiterated confidence in exceeding the 2024 guidance. With significant investments in U.S. manufacturing capacity and a new production facility in Hungary, SCHOTT Pharma aims to meet high market demand.
The DDS segment led revenue growth with a 33% increase to EUR 96 million. Despite currency headwinds, EBITDA remained strong due to strategic capacity expansions. The company confirmed its full year guidance for 9%-11% revenue growth and EBITDA margins comparable to the previous year.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SCHOTT Pharma AG & Co. KGaA news